Table 2.
36-month cumulative incidence of HPV among the cohort of 477 male university students, by circumcision status.
| HPV Type | Cumulative Incidence at 36 Months Among Circumcised Subjects (95% CI) |
No. Infections/ No. Person- years at Risk Among Circumcised Subjects |
Cumulative Incidence at 36 Months Among Uncircumcised Subjects (95% CI) |
No. Infections/ No. Person- years at Risk Among Uncircumcised Subjects |
|---|---|---|---|---|
| CRa | 62.6 (56.0, 70.0) | 143/ 403 | 66.2 (53.3, 78.7) | 45/ 124 |
| Any HRb | 61.6 (54.8, 68.4) | 142/ 412 | 66.2 (53.1, 78.8) | 45/ 126 |
| 6 | 14.2 (10.2, 19.6) | 34/ 646 | 13.9 (7.6, 24.7) | 11/ 218 |
| 11 | 2.7 (1.2, 5.7) | 7/ 688 | 0 | 0/ 230 |
| 16 | 26.3 (21.2, 32.2) | 71/ 579 | 35.4 (25.1, 48.3) | 29/ 187 |
| 18 | 19.4 (14.8, 25.4) | 46/ 603 | 14.4 (8.1, 24.9) | 11/ 203 |
| 26 | 0 | 0/ 699 | 1.3 (0.2, 9.1) | 1/ 233 |
| 31 | 8.1 (5.1, 12.6) | 19/ 658 | 10.3 (5.1, 20.3) | 8/ 214 |
| 33 | 7.7 (4.9, 12.2) | 18/ 678 | 7.2 (3.5, 14.7) | 7/ 223 |
| 35 | 1.8 (0.7, 4.8) | 4/ 695 | 5.2 (1.7, 15.4) | 3/ 233 |
| 39 | 9.8 (6.7, 14.4) | 25/ 653 | 10.5 (5.3, 20.5) | 8/ 224 |
| 45 | 7.5 (4.7, 12.0) | 17/680 | 6.0 (2.5, 14.0) | 5/ 226 |
| 51 | 25.5 (20.0, 32.2) | 57/ 620 | 18.6 (11.0, 30.4) | 14/ 204 |
| 52 | 6.1 (3.5, 10.2) | 13/ 677 | 10.3 (5.2, 20.0) | 8/ 223 |
| 53 | 13.3 (9.5, 18.7) | 31/ 656 | 14.3 (7.8, 25.5) | 11/ 221 |
| 56 | 14.3 (10.4, 19.7) | 34/ 655 | 13.9 (7.4, 25.6) | 9/ 223 |
| 58 | 4.1 (2.1, 7.9) | 9/ 682 | 6.5 (2.5, 16.4) | 4/ 232 |
| 59 | 6.7 (4.0, 11.0) | 15/ 669 | 2.7 (0.7, 10.5) | 2/ 232 |
| 66 | 13.1 (9.1, 18.6) | 29/ 658 | 11.2 (5.3, 22.6) | 7/ 224 |
| 68 | 1.7 (0.5, 5.2) | 3/ 697 | 0 | 0/ 235 |
| 73 | 6.2 (3.6, 10.3) | 14/ 686 | 6.7 (2.6, 16.4) | 5/ 222 |
| 82 | 4.4 (2.4, 7.8) | 11/ 685 | 6.1 (2.5, 14.2) | 5/ 229 |
| IS39 | 4.7 (2.5, 8.7) | 10/ 686 | 5.8 (2.2, 14.8) | 4/ 229 |
| Combinationsc | ||||
| 6/11 | 16.1 (11.9, 21.8) | 39/ 635 | 12.7 (6.7, 23.4) | 10/ 214 |
| 16/18 | 37.0 (31.2, 43.6) | 95/ 516 | 42.7 (31.5, 56.0) | 34/ 170 |
| 6/11/16/18 | 43.1 (36.7, 50.0) | 106/ 485 | 47.6 (35.9, 61.0) | 37/ 162 |
| alpha-9d | 38.1 (32.1, 44.9) | 95/ 532 | 44.7 (33.6, 57.7) | 35/ 164 |
| alpha-7e | 34.1 (28.1, 40.9) | 79/ 552 | 31.4 (21.8, 44.0) | 23/ 185 |
a
Clinically-relevant types were defined as high or probable high-risk types plus HPV6 and HPV11.
b
High or probable high risk types were defined as HPV16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82, and IS39, as defined in the cervical cancer literature.
c
First infection with any type in the combined group.
d
Alpha 9 group (HPV16, 31, 33, 35, 52, and 58; excluding low risk type HPV70).
e
Alpha 7 group (HPV18, 39, 45, 59, and 68; excluding low risk type HPV67).